SERATICIN® Antibacterial Technology Based on Maggot Secretions

project image

University:

Swansea University

Sector(s):

Chemical, Healthcare and Pharmaceuticals, Life Sciences


About The Opportunity:

Maggot secretions have been used for centuries to treat and clean wounds. At Swansea University a technology, trademarked under the name SERATICIN®, has been developed to treat various bacterial infections, including MRSA, using a synthetic, small-molecule version of an extract from maggot secretions. SERATICIN® offers the prospect of a highly effectively antibacterial candidate in a format compatible with modern drug delivery modes with minimal drug resistance and side-effects.

Applications:

  • The antibacterial technology is being developed for use in a topical format although it is hoped to advance an oral medication with further investment. It is expected to be used in both the animal and human antibiotic markets.

Key Benefits:

  • Early experiments indicate a strong and broad antibacterial potential;
  • Minimal drug resistance to a novel, first in class bactericidal agent;
  • Potential for a range of drug delivery mechanisms. 


IP Status:

A patent has been granted under application no. PCT/GB2008/000157 and a second patent on the chemical structure is pending under application no. PCT/GB2012/053138.

Offer:

The invention is offered for exclusive or non-exclusive licence.

See more at:

http://www.swanseainnovations.com/commercialisation-opportunities.htm?id=12

Back